Ponatinib is a multi-targeted TKI approved for human use in chronic myeloid leukemia (CML) [49] that has been shown to have broad activity against SRC family members including LCK [50]. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.